This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
The SOLUTION trial was supported by H. Lundbeck A/S.
Wang G, et al. Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder. Current Medical Research and Opinion : 28 Jan 2020. Available from: URL: https://doi.org/10.1080/03007995.2020.1723072
About this article
Cite this article
Vortioxetine in major depression: high success rates, acceptable cost. PharmacoEcon Outcomes News 846, 31 (2020). https://doi.org/10.1007/s40274-020-6570-6